Welcome to our dedicated page for Silence Therapeutics Plc news (Ticker: SLN), a resource for investors and traders seeking the latest updates and insights on Silence Therapeutics Plc stock.
Silence Therapeutics plc (Nasdaq: SLN) generates a steady flow of news as a global clinical-stage biotechnology company developing siRNA (short interfering RNA) therapies. Its updates focus on the progress of programs built on its proprietary mRNAi GOLD™ platform, which is designed to create precision engineered siRNAs that target and silence disease-associated genes in the liver.
Investors following SLN news can expect detailed coverage of clinical trial milestones, particularly for divesiran, the company’s first-in-class siRNA candidate for polycythemia vera (PV). Recent announcements describe additional Phase 1 data presented at major hematology meetings, durable hematocrit control and reduced need for phlebotomies in PV patients, and the completion of enrollment in the global, randomized SANRECO Phase 2 study.
Silence also issues news on its broader pipeline and strategy, including updates on zerlasiran for cardiovascular disease, extra-hepatic siRNA targeting work, and its collaboration program SLN312 licensed to AstraZeneca. Financial result press releases provide context on research and development spending, cash and investment balances, and the company’s stated cash runway expectations, alongside commentary on operational priorities.
Corporate governance and leadership developments feature in SLN news as well, such as changes to the Board of Directors, executive transitions and outcomes of shareholder votes at the annual general meeting. Conference participation announcements highlight company presentations at healthcare and investor events, where management discusses the siRNA platform, clinical data and pipeline priorities.
By monitoring this news page, readers can review a chronological record of Silence Therapeutics’ clinical, financial and corporate disclosures related to SLN, with an emphasis on the evolution of its siRNA programs in cardiovascular disease, hematology and rare diseases.
Silence Therapeutics has appointed Michael H. Davidson, MD, a lipidology expert, to its Board of Directors to bolster its development of SLN360, aimed at treating cardiovascular diseases. Dr. Davidson brings over 30 years of experience in clinical trials and has a notable history of founding and leading successful biotech companies, enhancing the expertise within Silence's pipeline. This strategic addition is expected to provide valuable insights as Silence advances its GalNAc siRNA platform and prepares for clinical progress with SLN360.
Silence Therapeutics has appointed Craig Tooman as its new Chief Financial Officer effective immediately. Tooman brings over 30 years of biopharmaceutical experience, including roles as CFO at Vyome Therapeutics and Aratana Therapeutics. His expertise in financial strategies and business development is expected to strengthen Silence's position in the RNAi market, especially as the company advances clinical candidates SLN360 and SLN124. CEO Mark Rothera emphasized the strategic timing of this appointment amid significant growth opportunities for the firm.
Silence Therapeutics (AIM: SLN, Nasdaq: SLN) announced its participation in two upcoming virtual U.S. investor conferences. The presentations will include a fireside chat at the H.C. Wainwright BioConnect 2021 Conference on January 11, 2021, at 6:00 a.m. EST, and at the ICR Conference 2021 on January 14, 2021, from 8:30-9:10 a.m. EST. Live webcasts can be accessed on the company's website, with archived replays available for 60 days post-event.
Silence is focused on siRNA therapeutics for significant unmet medical needs.
Silence Therapeutics presented positive pre-clinical data for SLN360 at the American Heart Association's 2020 conference. The data reveals no adverse effects, demonstrating safe biodistribution primarily in the liver and kidneys. SLN360 targets elevated lipoprotein(a), a genetic risk factor for cardiovascular diseases, and is set to enter in-human testing following promising results. The ongoing Phase I APOLLO trial aims to assess safety and efficacy in patients with elevated Lp(a) levels, potentially offering a novel treatment for this unmet medical need.
Silence Therapeutics (AIM:SLN, Nasdaq:SLN) has announced a significant change in its executive leadership, initiating a search for a U.S.-based Chief Financial Officer (CFO). Current CFO Rob Quinn will transition from the role in January 2021 to pursue a new opportunity. This change follows Silence's recent Nasdaq listing aimed at enhancing its U.S. market presence and engagements with investors. Mark Rothera, the CEO, emphasized this strategy to leverage U.S. growth potential, and Iain Ross, the Chairman, acknowledged the strong position left by Quinn.